TGFB1 and cancer: Quantification of the frequencies of αSMA-expressing CAFs using flow cytometric analysis also revealed a significant reduction in the numbers of myofibroblasts (Fig. 4d), suggesting that TGFβ- blockade may preferentially target cancer-associated myofibroblasts.